Tradestie Institutional Equity Comparison Engine

KMTS vs LMRI โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

KMTS Overall Edge

KMTS Captures Institutional Edge (1โ€“1 Pillars ยท 7โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Kestra Medical Technologies, Ltd. Common Stock (KMTS) driven by superior Growth & Margin while LMRI counters with relative strength in Momentum & Technical. Fundamentally, KMTS trades at N/M Forward P/E with -134.5% operating margin (+59.9% YoY revenue) versus LMRI at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, KMTS sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against LMRI sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
KMTS N/M vs LMRI N/M Fwd P/E
Growth & Margin Winner KMTS
Op Margin -134.5% vs N/A ยท YoY +59.9% vs N/A
Momentum & Technical Winner LMRI
1Y -2.8% vs -23.0% ยท 52W Pos 53% vs 60%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
KMTS NASDAQ
Kestra Medical Technologies, Ltd. Common Stock
Surgical & Medical Instruments & Apparatus
$25.10
-5.75% 1D
Market Cap $1.6B
1M Return -11.37%
1Y Return -2.83%
Forward P/E N/M
Unified AI Score
46.9 / 100 HOLD
Tech 37.0 Fund 43.0 Flow 50.0 Mom 60.0
LMRI US Equity
LMRI
Institutional Equity
$14.26
+1.42% 1D
Market Cap N/A
1M Return +30.95%
1Y Return -23.0%
Forward P/E N/M
Unified AI Score
32.1 / 100 SELL
Tech 50.0 Fund 30.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: KMTS -2.83% LMRI -23.0% Spread: +23.76 pp (KMTS Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
KMTS TTM Op. Margin: -134.5% LMRI TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on KMTS vs LMRI. Trailing 12-month operating profitability (KMTS -134.5% vs LMRI N/A) and valuation multiples (KMTS N/M vs LMRI N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: KMTS (7) vs LMRI (1)
Institutional Metric KMTS LMRI Criterion Row Winner
Market Capitalization Scale $1.6B N/A Larger Scale KMTS
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +59.9% N/A Higher Growth KMTS
Operating Margin (TTM) Profitability -134.5% N/A Higher Margin KMTS
Net Profit Margin Profitability -140.4% N/A Higher Margin KMTS
Return on Equity (ROE) Capital Efficiency -73.7% N/A Higher ROE KMTS
52-Week Range Position Momentum 53% ($17โ€“$32) 60% ($6โ€“$19) Stronger Trend LMRI
Beta / 30D Volatility Risk Regime 1.74ฮฒ ยท 63% Vol 1.22ฮฒ ยท 85% Vol Lower Realized Risk KMTS
Unified Institutional Score Composite Signal 46.9 / 100 (HOLD) 32.1 / 100 (SELL) Higher Composite KMTS

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full KMTS vs LMRI Buy Guide
KMTS UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live KMTS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
LMRI UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live LMRI Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither KMTS nor LMRI registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.